Leflunomide Sandoz (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated T‑ and B‑lymphocytes, thereby dampening the autoimmune inflammation that drives rheumatoid and psoriatic arthritis.

The exact dose of Leflunomide Sandoz is set by the prescribing clinician based on the patient’s disease severity, prior treatment response, liver function, and overall health status. The prescriber follows approved labeling and clinical guidelines to select an appropriate regimen.

Leflunomide is classified as pregnancy category X because it is teratogenic. It should not be used by pregnant women, and effective contraception is required for women of child‑bearing potential. Breastfeeding is not recommended while taking leflunomide.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both leflunomide and methotrexate are conventional DMARDs, but they act on different pathways. Methotrexate inhibits folate metabolism, whereas leflunomide blocks pyrimidine synthesis. Clinical choice depends on patient tolerance, liver function, and prior response; some patients who do not respond adequately to methotrexate may benefit from leflunomide.

Leflunomide tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and store out of reach of children.

Leflunomide Sandoz is taken orally as a tablet with a glass of water. The tablet is usually swallowed whole; it should not be crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include severe liver injury, bone‑marrow suppression (which can lead to neutropenia or anemia), pulmonary toxicity such as interstitial lung disease, and teratogenic effects that can cause birth defects. Prompt reporting of symptoms like jaundice, persistent fever, or unexplained bruising is essential.

Leflunomide should not be used by pregnant women, individuals with severe liver disease, patients with active serious infections, or those with known hypersensitivity to leflunomide or its excipients. Caution is also advised for patients with significant renal impairment or a history of bone‑marrow disorders.